{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T17:29:54.280493+00:00","company":{"ticker":"GPCR","cik":1888886,"company_name":"Structure Therapeutics Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"d03eb025238609f96a6ab68cd79971940f014504","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Structure Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057226","anchor_url":"https://secwatch.observer/filing/0001104659-26-057226#claim-d03eb025238609f96a6ab68cd79971940f014504","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm"},{"fact_type":"material_agreement","fact_key":"870d62963ed5eac350b3fc4d85c59218de766582","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended and Restated Sales Agreement","agreement_type":"atm_program","counterparty":"Leerink Partners LLC and Cantor Fitzgerald & Co.","effective_date":"2026-05-07","item_codes_triggered":["1.01"],"value_text":null},"claim":"Structure Therapeutics Inc. amended Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (effective 2026-05-07).","evidence_excerpt":"On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057226","anchor_url":"https://secwatch.observer/filing/0001104659-26-057226#claim-870d62963ed5eac350b3fc4d85c59218de766582","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm"},{"fact_type":"material_agreement","fact_key":"1508cca0995f76fb59514eef093108b23e803cb2","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2026-01-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"GNE Agreement","agreement_type":"license","counterparty":"Genentech, Inc. and F. Hoffmann-La Roche Ltd","effective_date":"2025-12-30","item_codes_triggered":["1.01"],"value_text":"$100 million"},"claim":"Structure Therapeutics Inc. entered into GNE Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $100 million (effective 2025-12-30).","evidence_excerpt":"On December 30, 2025, Gasherbrum Bio, Inc. (\"Gasherbrum\"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the \"Company\"), entered into an agreement (the \"GNE Agreement\") with Genentech, Inc. (\"Genentech\") and F. Hoffmann-La Roche Ltd (\"Roche\" and together with Genentech, \"GNE\") that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of Gasherbrum","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-000620","anchor_url":"https://secwatch.observer/filing/0001104659-26-000620#claim-1508cca0995f76fb59514eef093108b23e803cb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm"},{"fact_type":"executive_change","fact_key":"232a6b30db","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2024-09-17T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-18","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Mark Bach departed as Chief Medical Officer at Structure Therapeutics Inc..","evidence_excerpt":"On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-100668","anchor_url":"https://secwatch.observer/filing/0001104659-24-100668#claim-232a6b30db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924100668/0001104659-24-100668-index.htm"},{"fact_type":"executive_change","fact_key":"744266cdb9","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2024-08-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-26","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Angus Russell was appointed as Class I director at Structure Therapeutics Inc..","evidence_excerpt":"appointed Angus Russell to the Board, effective August 26, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-093434","anchor_url":"https://secwatch.observer/filing/0001104659-24-093434#claim-744266cdb9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924093434/0001104659-24-093434-index.htm"},{"fact_type":"earnings_release","fact_key":"cd4e8fa2b81af8272d671ffa45dcbdd77521c31f","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter of 2024 totaled $26.0 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Structure Therapeutics Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 totaled $26.0 million.","evidence_excerpt":"Structure Therapeutics Inc. (the \"Company\") issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-059329","anchor_url":"https://secwatch.observer/filing/0001104659-24-059329#claim-cd4e8fa2b81af8272d671ffa45dcbdd77521c31f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm"},{"fact_type":"earnings_release","fact_key":"8296476bd1886f7a06a23ec5ec41bfbfd5994994","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2024-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"For the year ended December 31, 2023, net loss totaled $89.6 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-08","result_type":"reported_results","revenue_text":null},"claim":"Structure Therapeutics Inc. reported the year ended December 31, 2023 results: net income For the year ended December 31, 2023, net loss totaled $89.6 million.","evidence_excerpt":"For the year ended December 31, 2023, net loss totaled $89.6 million, with non-cash stock-based compensation expense of $8.2 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-032121","anchor_url":"https://secwatch.observer/filing/0001104659-24-032121#claim-8296476bd1886f7a06a23ec5ec41bfbfd5994994","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm"},{"fact_type":"earnings_release","fact_key":"748304e4d17f440ef81a9ddf1c70cbea3746efb8","cik":1888886,"ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2024-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the fourth quarter of 2023 totaled $24.5","period_text":"the fourth quarter of 2023","report_date":"2024-03-08","result_type":"reported_results","revenue_text":null},"claim":"Structure Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net loss for the fourth quarter of 2023 totaled $24.5.","evidence_excerpt":"Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-032121","anchor_url":"https://secwatch.observer/filing/0001104659-24-032121#claim-748304e4d17f440ef81a9ddf1c70cbea3746efb8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm"}]}